title: The effects of different antioxidants on the activity of cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer's disease and age-matched normal brains.
abstract: Among the markers and targets of the early phase of Alzheimer's disease (AD) pathogenesis MnSOD (mitochondrial dysfunction) and Na-pump (disturbances in function/regulation) are often highlighted. This paper focused on comparison of the effects of three antioxidants on the activity of cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer's disease and age-matched normal brains. Antioxidant compounds with different origins: natural glutathione, synthetic UPF peptides (glutathione analogues) and phytoestrogen genistein were investigated. Firstly, MnSOD and Na,K-ATPase activities were found to be decreased in the post mortem AD brains compared with age-matched controls. Secondly, GSH had no effect on MnSOD activity, but decreased Na,K-ATPase activity both in the control and AD brains. Thirdly, UPF1 and UPF17 increased MnSOD activity, and UPF17 suppressed Na,K-ATPase activity. Further studies are needed to clarify, if the inhibitory effect of UPF17 on Na,K-ATPase could abolish the beneficial effect gained from MnSOD activation. Both the antioxidative potential of genistein and its potency to up-regulate Na,K-ATPase activity make it an attractive candidate substance to suppress the early phase of the pathogenesis of AD.
authors.forename: C
authors.initials: C
authors.lastname: Kairane
authors.forename: R
authors.initials: R
authors.lastname: Mahlapuu
authors.forename: K
authors.initials: K
authors.lastname: Ehrlich
authors.forename: M
authors.initials: M
authors.lastname: Zilmer
authors.affiliation: Department of Biochemistry, Faculty of Medicine, University of Tartu, The Centre of Excellence of Translational Medicine, Ravila Str. 19, Tartu, 50411, Estonia. kersti.ehrlich@ut.ee.
authors.forename: U
authors.initials: U
authors.lastname: Soomets
mesh_terms: D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology*; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D005625:Frontal Lobe / Q000187:drug effects* / Q000201:enzymology; D019833:Genistein / Q000627:therapeutic use; D005978:Glutathione / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000378:metabolism*; D013702:Temporal Lobe / Q000187:drug effects* / Q000201:enzymology
chemical_list: C529051:4-methoxy-1-tyrosyl-gamma-glutamyl-cysteinyl-glycine; D000975:Antioxidants; D009842:Oligopeptides; C000591901:Upf17 peptide; D019833:Genistein; D013482:Superoxide Dismutase; D000254:Sodium-Potassium-Exchanging ATPase; D005978:Glutathione